Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Palonosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 10/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palonosetron SCHEMBL29402278 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL4058558 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL7782594 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL7277880 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL10066801 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL3748 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL13240607 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL4052980 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL3747 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL3746 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100174080-A1 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | CHEMAGIS LTD. (IL) | 2010-07-08 | — | — | US | claimed |
| EP-2155199-A2 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | Chemagis Ltd. (IL) | 2010-02-24 | — | — | EP | claimed |
| WO-2008146283-A2 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | CHEMAGIS LTD. (IL) | 2008-12-04 | — | — | WO | claimed |
| EP-0770077-B1 | PROCESS FOR THE PREPARATION OF 2-(1-AZABICYCLO(2.2.2)OCT-3-YL) -2,4,5,6-TETRAHYDRO-1H-BENZ(DE)ISOQUINOLIN-1-ONE AND INTERMEDIATE PRODUCT | HOFFMANN LA ROCHE (CH) | 2001-09-19 | — | — | EP | claimed |
| EP-0770077-A1 | PROCESS FOR THE PREPARATION OF 2-(1-AZABICYCLO(2.2.2)OCT-3-YL) -2,4,5,6-TETRAHYDRO-1H-BENZ(DE)ISOQUINOLIN-1-ONE AND INTERMEDIATE PRODUCT | F. HOFFMANN-LA ROCHE AG (CH) | 1997-05-02 | — | — | EP | claimed |
| US-5567818-A | Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein | SYNTEX (U.S.A.) INC. (US) | 1996-10-22 | — | — | US | claimed |
| WO-1996001824-A1 | PROCESS FOR THE PREPARATION OF 2-(1-AZABICYCLO(2.2.2)OCT-3-YL) -2,4,5,6-TETRAHYDRO-1H-BENZ(DE)ISOQUINOLIN-1-ONE AND INTERMEDIATE PRODUCT | F. HOFFMANN-LA ROCHE AG (CH) | 1996-01-25 | — | — | WO | claimed |
| EP-0430190-B1 | New tricyclic compounds | SYNTEX INC (US) | 1995-07-05 | — | — | EP | claimed |
| US-5202333-A | Tricyclic 5-HT3 receptor antagonists | SYNTEX (U.S.A.) INC. (US) | 1993-04-13 | — | — | US | claimed |
| EP-0430190-A2 | New tricyclic compounds | SYNTEX (U.S.A.) INC. (US) | 1991-06-05 | — | — | EP | claimed |
| CN-108721214-B | Netupidan and palonosetron compound nanoparticle solution, nanoparticles, preparation method and application | 和龙 | 2020-06-16 | — | — | CN | disclosed |
| US-20130079521-A1 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | CHEMAGIS LTD. (IL) | 2013-03-28 | — | — | US | disclosed |
| US-20130079521-A1 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | CHEMAGIS LTD. (IL) | 2013-03-28 | — | — | US | disclosed |
| US-8334388-B2 | Palonosetron salts and processes for preparation and purification thereof | CHEMAGIS LTD. (IL) | 2012-12-18 | — | — | US | disclosed |
| US-8334388-B2 | Palonosetron salts and processes for preparation and purification thereof | CHEMAGIS LTD. (IL) | 2012-12-18 | — | — | US | disclosed |
| EP-0770077-B1 | PROCESS FOR THE PREPARATION OF 2-(1-AZABICYCLO(2.2.2)OCT-3-YL) -2,4,5,6-TETRAHYDRO-1H-BENZ(DE)ISOQUINOLIN-1-ONE AND INTERMEDIATE PRODUCT | HOFFMANN LA ROCHE (CH) | 2001-09-19 | — | — | EP | disclosed |
| EP-0770077-A1 | PROCESS FOR THE PREPARATION OF 2-(1-AZABICYCLO(2.2.2)OCT-3-YL) -2,4,5,6-TETRAHYDRO-1H-BENZ(DE)ISOQUINOLIN-1-ONE AND INTERMEDIATE PRODUCT | F. HOFFMANN-LA ROCHE AG (CH) | 1997-05-02 | — | — | EP | disclosed |
| US-5576434-A | (1-azabicyclo[2.2.2]oct-3-yl) (1,2,3,4-tetrahydronaphthalen-1-ylmethyl)amine and n-(1-azabicyclo[2.2.2]oc | HELSINN HEALTHCARE SA (CH) | 1996-11-19 | — | — | US | disclosed |
| US-5567818-A | Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein | SYNTEX (U.S.A.) INC. (US) | 1996-10-22 | — | — | US | disclosed |
| WO-1996001824-A1 | PROCESS FOR THE PREPARATION OF 2-(1-AZABICYCLO(2.2.2)OCT-3-YL) -2,4,5,6-TETRAHYDRO-1H-BENZ(DE)ISOQUINOLIN-1-ONE AND INTERMEDIATE PRODUCT | F. HOFFMANN-LA ROCHE AG (CH) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174080-A1 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | HTR3C, HTR3A, CYP3A43 | HTR3A 2/4885HTR3B 4/4885ADRA2A 96/4885 |
| US-20130079521-A1 | NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF | HTR3C, HTR3A, CYP3A43 | HTR3A 2/4885HTR3B 4/4885ADRA2A 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.